Evotec SE (EVT)

Overview

Evotec SE is a global drug discovery and development company, serving the pharmaceutical and biotechnology industry with innovative solutions. It engages in developing a comprehensive range of pharmaceutical products aimed at addressing various therapeutic areas including diabetes and its complications, fibrosis, infectious diseases, central nervous system (CNS) diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. The company has established numerous collaboration agreements with major industry players such as Bayer, Lilly, Almirall, and Pfizer Inc., among others. Additionally, Evotec SE has entered strategic partnerships to enhance its oncology pipeline and develop next-generation therapeutic solutions, notably with Dewpoint Therapeutics and Glycotope GmbH. Originally founded in 1993 as Evotec AG, the company transitioned to its current name, Evotec SE, in April 2019 and is headquartered in Hamburg, Germany.

Products and Services

Evotec SE offers a broad spectrum of products and services across various therapeutic areas:

• Diabetes and complications: Evotec proposes innovative treatment solutions aimed at managing diabetes and preventing its complications, contributing to improved patient outcomes.
• Fibrosis: Focusing on the development of therapies to treat fibrotic diseases, Evotec aims to halt the progression of these often life-altering conditions.
• Infectious diseases: By discovering and developing drugs for infectious diseases, Evotec helps combat emerging global health threats.
• CNS diseases: The company is committed to addressing unmet needs in central nervous system disorders, offering hope for patients suffering from debilitating conditions.
• Oncology: Evotec is actively involved in creating innovative cancer treatments with the potential to significantly improve patient survival rates and quality of life.
• Pain and inflammation: Developing solutions for pain management and inflammatory diseases, Evotec works to enhance life quality for affected individuals.
• Immunology: Through its efforts in immunology, Evotec aims to advance treatments for immune-mediated diseases, focusing on innovative therapeutic approaches.
• Rare diseases: The company takes on the challenge of targeting rare diseases, offering new avenues of hope for patients with limited treatment options.
• Respiratory diseases: Evotec's work in the respiratory domain seeks to improve the treatment landscape for patients with chronic respiratory conditions.
• Women's health: Addressing the unique health needs of women, Evotec dedicates resources to developing targeted therapies in areas like fertility and gynecological diseases.

Furthermore, Evotec SE's strategic partnerships and collaborations, such as with Dewpoint Therapeutics for oncology pipelines and Glycotope GmbH for immune cell engaging bispecifics, are pivotal in advancing its mission to bring novel therapeutic options to market, notably in the treatment of solid tumors.